Plasma proteomics of differential outcome to long‐term therapy in children with idiopathic pulmonary arterial hypertension

Authors:

Abstract
Purpose: The prognosis for children with IPAH unresponsive to therapy is poor. We investigated the plasma proteome for a molecular basis of good versus poor outcome to long‐term vasodilator therapy.Experimental design: Plasma was collected at baseline or shortly after therapy initiation and following chronic vasodilator therapy, then divided into those with good outcome (n = 8), and those with a poor outcome (n = 7). To identify proteins unique to either outcome, we used differential gel electrophoresis and mass spectrometry. Results were confirmed by commercial enzyme‐linked immunosorbent assay.Results: Before and after therapy, SAA‐4 was 4‐fold lower in those with good outcome compared to those with poor outcome, while serum paraoxonase/arylesterase‐1 was increased 2‐fold in those with good outcome versus poor outcome. After therapy, haptoglobin and hemopexin were 1.45‐ and 1.8‐fold lower, respectively, in those with a good versus poor outcome. Among those with a good outcome, SAP was 1.3‐fold lower prior to therapy.Conclusions and clinical relevance: SAP and SAA‐4 regulate circulating mononuclear phagocytes. As such, they may contribute to the differential response to chronic vasodilator therapy in the context of inflammation in IPAH.
Funding Information
  • National Institutes of Health (NIH) Specialized Centers of Clinically Oriented Research (HL-084923-02)
  • NIH (HL-014985-35)
  • Jayden DeLuca Foundation (M01-RR00069)

This publication has 61 references indexed in Scilit: